HM-002

HM-002 is a preclinical-stage therapeutic candidate being developed by the Japanese biotechnology company HOIST for the treatment of malignant peritonitis and peritoneal dissemination (peritoneal carcinomatosis). While specific details regarding its molecular target and active pharmaceutical ingredient have not been publicly disclosed, the program is part of HOIST's oncology pipeline, which focuses on addressing advanced abdominal malignancies that have spread to the peritoneal cavity. The drug likely leverages HOIST's core expertise in specialized drug delivery systems, such as nanocrystal formulations, designed to optimize the efficacy of antineoplastic agents when administered directly into the abdominal space. As of late 2024, HM-002 remains in early development as a follow-on or complementary program to the company's lead asset, HM-001.